Table 2.
Unadjusted and Adjusted Risk of Death for Stage I NSCLC (N = 65,957)
| Variable | No. | Unadjusted Risk HR (95% CI) |
Adjusted Riska HR (95% CI) |
Adjusted With Interactionb HR (95% CI) |
|---|---|---|---|---|
| Yearly increment | … | 0.962 (0.958–0.965) | 0.965 (0.962–0.969) | NA |
| Age at diagnosisc | … | 1.043 (1.042–1.044) | 1.028 (1.027–1.029) | 1.028 (1.027–1.029) |
| Sex | ||||
| Female (reference) | 32,833 | 1.000 | 1.000 | 1.000 |
| Male | 33,124 | 1.334 (1.307–1.361) | 1.378 (1.348–1.407) | 1.378 (1.348–1.407) |
| Race | ||||
| White (reference) | 56,240 | 1.000 | 1.000 | 1.000 |
| Black | 6,108 | 1.168 (1.129–1.208) | 1.045 (1.010–1.082) | 1.043 (1.008–1.080) |
| Other | 3,609 | 0.794 (0.757–0.834) | 0.799 (0.761–0.839) | 0.800 (0.762–0.840) |
| Marital status | ||||
| Married (reference) | 35,550 | 1.000 | 1.000 | 1.000 |
| Not married | 30,407 | 1.326 (1.300–1.353) | 1.181 (1.156–1.207) | 1.182 (1.157–1.208) |
| Histologic finding | ||||
| Adeno (reference) | 25,674 | 1.000 | 1.000 | 1.000 |
| Squamous | 18,589 | 1.581 (1.542–1.622) | 1.279 (1.247–1.312) | 1.278 (1.246–1.312) |
| Large cell | 2,490 | 1.510 (1.434–1.590) | 1.303 (1.237–1.373) | 1.299 (1.233–1.369) |
| Others | 19,204 | 1.509 (1.472–1.548) | 1.052 (1.026–1.080) | 1.049 (1.022–1.077) |
| Treatment | ||||
| No surgery or radiation (reference) | 11,537 | 1.000 | 1.000 | NA |
| Surgery only | 42,242 | 0.195 (0.190–0.200) | 0.230 (0.224–0.236) | NA |
| Radiation only | 10,048 | 0.690 (0.670–0.711) | 0.680 (0.660–0.700) | NA |
| Surgery and radiation | 2,130 | 0.364 (0.344–0.385) | 0.429 (0.406–0.455) | NA |
| Yearly increment by treatment group | ||||
| No surgery or radiation | … | NA | NA | 0.992 (0.986–0.998) |
| Surgery only | … | NA | NA | 0.959 (0.954–0.964) |
| Radiation only | … | NA | NA | 0.942 (0.935–0.949) |
| Surgery and radiation | … | NA | NA | 0.980 (0.962–0.997) |
a
Refers to estimated HRs generated in multiple variable model that included year, age, sex, race, marital status, histologic finding, and treatment.
b
Refers to the aforementioned adjustments in addition to an adjustment for the interaction between year and treatment, which yields an annualized overall survival with the prior year as the reference.
c
Median 70 years, range: 40 to 105 years.
Adeno = adenocarcinoma; CI = confidence interval; HR = hazard ratio; NA = not applicable; NSCLC = non-small cell lung cancer.